Mohan H M, Ryan E, Balasubramanian I, Kennelly R, Geraghty R, Sclafani F, Fennelly D, McDermott R, Ryan E J, O'Donoghue D, Hyland J M P, Martin S T, O'Connell P R, Gibbons D, Winter Des, Sheahan K
Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland; School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland.
Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Eur J Surg Oncol. 2016 Nov;42(11):1680-1686. doi: 10.1016/j.ejso.2016.05.013. Epub 2016 Jun 22.
Up to 15% of colorectal cancers exhibit microsatellite instability (MSI), where errors in replication go unchecked due to defects in the mismatch repair system. This study aimed to determine survival in a large single-centre series of 1250 consecutive colorectal cancers subjected to universal MSI testing.
Clinical and pathological features of patients with colorectal cancer identified on prospectively maintained colorectal and pathology databases at St. Vincent's University Hospital from 2004 to May 2012 were examined. Mismatch repair (MMR) status was determined by immunohistochemistry. Kaplan-Meier curves, the log-rank test and Cox regression were used to associate survival with clinical and pathological characteristics.
Of the 1250 colorectal cancers in the study period, 11% exhibited MSI (n = 138). Patients with MSI tumours had significantly lower rates of lymph node and distant metastases (MSI N+ rate: 24.8% compared with MSS N+ rate: 46.2%, p < 0.001). For Stage I and II disease MSI was associated with improved disease free survival (DSS) compared with MSS colon cancer. However, patients with Stage III MSI colon cancers had a worse DSS than those with MSS tumours. Stage III MSI tumours exhibited higher rates of lymphovascular invasion and perineural invasion than Stage I/II MSI tumours.
MSI is associated with a reduced risk of nodal and distant metastases, with an improved DSS in Stage I/II colon cancer. However, when MSI tumours progress to Stage III these patients had worse outcomes and pathological features. New strategies for this cohort of patients may be required to improve outcomes.
高达15%的结直肠癌表现出微卫星不稳定性(MSI),即由于错配修复系统缺陷,复制过程中的错误未得到检查。本研究旨在确定对1250例连续的结直肠癌进行普遍MSI检测的大型单中心系列研究中的生存率。
对2004年至2012年5月在圣文森特大学医院前瞻性维护的结直肠癌和病理数据库中确定的结直肠癌患者的临床和病理特征进行检查。通过免疫组织化学确定错配修复(MMR)状态。使用Kaplan-Meier曲线、对数秩检验和Cox回归将生存率与临床和病理特征相关联。
在研究期间的1250例结直肠癌中,11%表现出MSI(n = 138)。MSI肿瘤患者的淋巴结转移和远处转移率显著较低(MSI N+率:24.8%,而MSS N+率:46.2%,p < 0.001)。对于I期和II期疾病,与MSS结肠癌相比,MSI与改善的无病生存率(DSS)相关。然而,III期MSI结肠癌患者的DSS比MSS肿瘤患者更差。III期MSI肿瘤的淋巴管侵犯和神经周围侵犯率高于I/II期MSI肿瘤。
MSI与淋巴结转移和远处转移风险降低相关,I/II期结肠癌的DSS得到改善。然而,当MSI肿瘤进展到III期时,这些患者的预后和病理特征较差。可能需要针对这组患者的新策略来改善预后。